PATENTS

IL-1β/MMP-7 treatment of cystitis:

Claims cover the use of IL-1β inhibitors (such as Anakinra) and/or  MMP-7 inhibitors in the treatment of cystitis.

NKR1 antagonists:

Claims cover the use of NK1R antagonists alone or in combination with Anakinra in the treatment of infections.

IRF7 inhibition:

IRF-7 inhibitors and in particular, siRNA molecules are effective in the treatment of bacterial infections and in particular, kidney infections. Broader claims should be allowed.

Pol II inhibitors:

Claims cover the use of named substances from commensal bacteria to be exploited in immunosuppression as well as in anti-inflammatory and anti-infective therapies.

Title Filing Date Country Patent Comments
IL-1β / MMP-7 treatment of cystitis
January 2016 Australia 2016205864 IL-1β inhibitors (such as Anakinra) and/or MMP-7 inhibitors in the treatment of cystitis.
Europe 16703357.0 and 9186921.3
USA 15/542,041
NK1R antagonists
June 2017 Australia 2017292391 NK1R antagonists alone or in combination with Anakinra in the treatment of infections.
Europe 17740488.6
USA 16/316,324
IRF7 inhibition
March 2016 Australia 2016241555 IRF-7 inhibitors and in particular, siRNA molecules are effective in the treatment of bacterial infections and in particular, kidney infections.
Europe 16715897.1
USA 10,287,585 (granted)
Pol II inhibitors
October 2017 Australia 2017344453 Named substances from commensal bacteria to be exploited in immunosuppression as well as in anti-inflammatory and anti-infective therapies.
Europe 17797991.1
India 20194718316
Singapore 11201903336U
USA 16/341,962
UPEC inhibitors
October 2017 Australia 2017342234 This application is directed to the use of anti-inflammatory molecules from bacteria.
Europe 17794419.6
India 201947018317
Singapore 11201903297R
USA 16/341,248